» Articles » PMID: 39753207

Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) As Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation

Overview
Journal ACS Chem Biol
Specialties Biochemistry
Biology
Date 2025 Jan 3
PMID 39753207
Authors
Affiliations
Soon will be listed here.
Abstract

Small molecule degraders such as PROteolysis TArgeting Chimeras (PROTACs) and molecular glues are new modalities for drug development and important tools for target validation. When appropriately optimized, both modalities lead to proteasomal degradation of the protein of interest (POI). Due to the complexity of the induced multistep degradation process, controls for degrader evaluation are critical and commonly used in the literature. However, comparative studies and evaluations of cellular potencies of these control compounds have not been published so far. Here, we investigated a diverse set of ubiquitin pathway inhibitors and evaluated their potency and utility within the CRBN and VHL-mediated degradation pathway. We used the HiBiT system to measure the level of target rescue after treatment with the control compounds. In addition, the cell health was assessed using a multiplexed high-content assay. These assays allowed us to determine nontoxic effective concentrations for control experiments and to perform rescue experiments in the absence of cellular toxicity.

Citing Articles

Workflow for E3 Ligase Ligand Validation for PROTAC Development.

Miletic N, Weckesser J, Mosler T, Rathore R, Hoffmann M, Gehrtz P ACS Chem Biol. 2025; 20(2):507-521.

PMID: 39932098 PMC: 11851430. DOI: 10.1021/acschembio.4c00812.

References
1.
Tjaden A, Giessmann R, Knapp S, Schroder M, Muller S . High-content live-cell multiplex screen for chemogenomic compound annotation based on nuclear morphology. STAR Protoc. 2022; 3(4):101791. PMC: 9617200. DOI: 10.1016/j.xpro.2022.101791. View

2.
Maharjan S, Oku M, Tsuda M, Hoseki J, Sakai Y . Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep. 2014; 4:5896. PMC: 4116626. DOI: 10.1038/srep05896. View

3.
Li K, Crews C . PROTACs: past, present and future. Chem Soc Rev. 2022; 51(12):5214-5236. PMC: 10237031. DOI: 10.1039/d2cs00193d. View

4.
Roy M, Winkler S, Hughes S, Whitworth C, Galant M, Farnaby W . SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. ACS Chem Biol. 2019; 14(3):361-368. PMC: 6423499. DOI: 10.1021/acschembio.9b00092. View

5.
Schwalm M, Kramer A, Dolle A, Weckesser J, Yu X, Jin J . Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization. Cell Chem Biol. 2023; 30(7):753-765.e8. DOI: 10.1016/j.chembiol.2023.06.002. View